| Autor: |
Irfan Ullah, Syeda Tayyaba Rehan, Zayeema Khan, Syed Hasan Shuja, Muhammad Hamza Shuja, Muhammad Irfan, Karthik Gonuguntla, M Chadi Alraies, Pratik Aggarwal, Sameer Raina, Yasar Sattar, Muhammad Sohaib Asghar |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
International Journal of Cardiology: Heart & Vasculature, Vol 53, Iss , Pp 101467- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2352-9067 |
| DOI: |
10.1016/j.ijcha.2024.101467 |
| Popis: |
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder with risk of sudden cardiac death (SCD) in children and adolescents. Mavacamten, also referred to as MYK-461, a myosin inhibitor of cardiac myocytes is studied in symptomatic HCM. The safety and efficacy of this medication is not well studied in pooled meta-analysis. Online database search was performed from inception to September 2023. We selected randomized clinical trials that compared Mavacamten with placebo/guideline medical treatment for HCM. We studied safety outcomes (Serious adverse events (SAEs), treatment emergent adverse events (TEAs) and Atrial fibrillation). Functional status of patients was assessed as New York Heart Association (NYHA) Classification improvement of at least + 1 grade, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) change from baseline). Relative risk ratios were used in randomized model using Review Manager Version 5.4 statistical software. A total of 4 RCTs comprising 503 patients were included in meta-analysis. On random effect model, we found that HCM patients that received Mavacamten had significant symptomatic improvement as depicted by improvement in NYHA class by at least + 1 grade (RR = 2.15; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
